手機APP下載

您現在的位置: 大陸口罩寄到香港 > 在線廣播 > VOA慢速英語 > VOA慢速-健康報道 > 正文

VOA慢速英語(翻譯+字幕+講解):禮來公司尋求實驗性新冠肺炎抗體藥物獲批

來源:可可英語 編輯:aimee   VIP免費外教試聽課 |  可可官方微信:ikekenet
 下載MP3到電腦  批量下載MP3和LRC到手機
加載中..
IAFvC-rhXX!!dcz*6P

X=_6SlNigo6.

Eli Lilly Seeks Approval for Experimental COVID-19 Antibody Drug
Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.
Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.
The company announced the study's partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.
The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.
Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.
Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes."

oN%BJoZRaYtz

禮來新冠藥申請緊急使用授權.jpeg
The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.
The medical news website StatNews reported that "Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust."
The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.
At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president's personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.
Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year's end.
The drug maker added that it is also "working with regulators around the world to make these treatments available."
I'm Jonathan Evans.

l4%NkIIcOhyhAOFFOY

iIl!&2z|Z@vJ5zuRU+

#-jOLc=Do8^,Wo6]O1s*HylZ([kuF.eN5|s+*NnsNC6b+LGv

重點單詞   查看全部解釋    
therapy ['θerəpi]

想一想再看

n. 療法,治療

 
limited ['limitid]

想一想再看

adj. 有限的,被限制的
動詞limit的過

 
experimental [iks.peri'mentl]

想一想再看

adj. 實驗(性)的,試驗(性)的

 
announced [ə'naunst]

想一想再看

宣佈的

 
sufficient [sə'fiʃənt]

想一想再看

adj. 足夠的,充分的

聯想記憶
combination [.kɔmbi'neiʃən]

想一想再看

n. 結合,聯合,聯合體

聯想記憶
inaccurate [in'ækjurit]

想一想再看

adj. 不準確的,錯誤的

 
statement ['steitmənt]

想一想再看

n. 聲明,陳述

聯想記憶
mild [maild]

想一想再看

adj. 温和的,柔和的

 
approval [ə'pru:vəl]

想一想再看

n. 批准,認可,同意,贊同

聯想記憶
發佈評論我來説2句

    最新文章

    可可英語官方微信(微信號:ikekenet)

    每天向大家推送短小精悍的英語學習資料.

    添加方式1.掃描上方可可官方微信二維碼。
    添加方式2.搜索微信號ikekenet添加即可。